News
News
VitaDX and MEDIPATH collaborate to deploy VisioCyt® , an innovative solution for the early diagnosis of bladder cancer
6 July 2022 -
VitaDX is proud to announce its partnership with Medipath, a group of independant pathologists specialized in locally based diagnostics and…
UC3: VitaDX, Cerballiance Finistère and the COSS laboratory are collaborating within the framework of the "Collaborative innovation at the crossroads of different sectors" initiative.
14 May 2019 -
The Characterisation of Urothelial Cancer Cells "UC3" project funded by the Brittany region, Rennes Métropole and the ERDF aims to deepen our…
VitaDX and MEDIPATH collaborate to deploy VisioCyt® , an innovative solution for the early diagnosis of bladder cancer
6 July 2022 -
VitaDX is proud to announce its partnership with Medipath, a group of independant pathologists specialized in locally based diagnostics and…
UC3: VitaDX, Cerballiance Finistère and the COSS laboratory are collaborating within the framework of the "Collaborative innovation at the crossroads of different sectors" initiative.
14 May 2019 -
The Characterisation of Urothelial Cancer Cells "UC3" project funded by the Brittany region, Rennes Métropole and the ERDF aims to deepen our…